Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centreCitation formats

Standard

Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre. / Warren, R. B.; Brown, B. C.; Lavery, D.; Griffiths, C. E M.

In: British Journal of Dermatology, Vol. 163, No. 4, 10.2010, p. 859-862.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Warren, R. B. ; Brown, B. C. ; Lavery, D. ; Griffiths, C. E M. / Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre. In: British Journal of Dermatology. 2010 ; Vol. 163, No. 4. pp. 859-862.

Bibtex

@article{28df509b8067489daff37819eb6bf12c,
title = "Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre",
abstract = "SummaryBackground There are few reports of the practical use of adalimumab outside a clinical trial setting and, to our knowledge, none from the U.K. Objectives We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. Methods A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. Results Mean ± SD baseline Psoriasis Area and Severity Index (PASI) score was 24 ± 11 (range 9-54; n = 46). After 4 months' treatment with adalimumab, 64{\%} (29/45) of patients had achieved PASI 75 (75{\%} decrease from baseline) while 80{\%} (36/45) of patients met National Institute for Health and Clinical Excellence (NICE) criteria for continuation of treatment. The therapy was well tolerated. Importantly, 68{\%} (21/31) of patients who had previously received another tumour necrosis factor-α inhibitor met NICE criteria for continuation of treatment at 16 weeks. Conclusions In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs. {\circledC} 2010 British Association of Dermatologists.",
keywords = "adalimumab, biological therapy, psoriasis",
author = "Warren, {R. B.} and Brown, {B. C.} and D. Lavery and Griffiths, {C. E M}",
year = "2010",
month = "10",
doi = "10.1111/j.1365-2133.2010.09986.x",
language = "English",
volume = "163",
pages = "859--862",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "John Wiley & Sons Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre

AU - Warren, R. B.

AU - Brown, B. C.

AU - Lavery, D.

AU - Griffiths, C. E M

PY - 2010/10

Y1 - 2010/10

N2 - SummaryBackground There are few reports of the practical use of adalimumab outside a clinical trial setting and, to our knowledge, none from the U.K. Objectives We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. Methods A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. Results Mean ± SD baseline Psoriasis Area and Severity Index (PASI) score was 24 ± 11 (range 9-54; n = 46). After 4 months' treatment with adalimumab, 64% (29/45) of patients had achieved PASI 75 (75% decrease from baseline) while 80% (36/45) of patients met National Institute for Health and Clinical Excellence (NICE) criteria for continuation of treatment. The therapy was well tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor-α inhibitor met NICE criteria for continuation of treatment at 16 weeks. Conclusions In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs. © 2010 British Association of Dermatologists.

AB - SummaryBackground There are few reports of the practical use of adalimumab outside a clinical trial setting and, to our knowledge, none from the U.K. Objectives We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. Methods A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. Results Mean ± SD baseline Psoriasis Area and Severity Index (PASI) score was 24 ± 11 (range 9-54; n = 46). After 4 months' treatment with adalimumab, 64% (29/45) of patients had achieved PASI 75 (75% decrease from baseline) while 80% (36/45) of patients met National Institute for Health and Clinical Excellence (NICE) criteria for continuation of treatment. The therapy was well tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor-α inhibitor met NICE criteria for continuation of treatment at 16 weeks. Conclusions In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs. © 2010 British Association of Dermatologists.

KW - adalimumab

KW - biological therapy

KW - psoriasis

U2 - 10.1111/j.1365-2133.2010.09986.x

DO - 10.1111/j.1365-2133.2010.09986.x

M3 - Article

VL - 163

SP - 859

EP - 862

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 4

ER -